報價延遲最少15分鐘:2026/04/15 17:33 EDT
盤後時段
|
||||
|
35.37 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
35.37
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.32/0.88
|
|
企業價值
1.87B
|
| 資產負債 |
|
每股賬面淨值
6.96
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
--
|
|
每股收益
3.64
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions. |
